Novlead Biotech develops nitric oxide (NO) therapies, including inhalation systems and wound-healing gas treatments, to enhance respiratory health and accelerate tissue repair. Their solutions address critical care needs and improve patient outcomes in emergency settings, while also offering consumer healthcare products for various applications.
Funding
Funding not disclosed
Founders
Product
Problem
Nitric oxide (NO) therapies, crucial for respiratory health and tissue repair, often lack accessibility and convenience in emergency and consumer healthcare settings. Existing delivery methods may be cumbersome, expensive, or not readily available for diverse applications.
Solution
Novlead Biotech develops and commercializes a range of nitric oxide (NO) therapies, including inhalation systems and wound-healing gas treatments, designed to enhance respiratory health and accelerate tissue repair. Their product line spans from emergency and critical care solutions, such as NO inhalation therapy devices and ECMO training simulation systems, to consumer healthcare products like HPV inhibition gel, nasal salts, and anti-hangover tablets. By leveraging their core NO technology, Novlead Biotech aims to provide accessible and effective NO-based solutions for both clinical and everyday use.
Target Audience
The primary target audience includes hospitals and emergency care providers needing advanced respiratory support, as well as consumers seeking accessible healthcare products for wound healing, hygiene, and general wellness.
Features
- iNOwill Series: NO inhalation therapy devices for clinical use.
- eNOaire Series: NO inhalation therapy devices.
- VQfit: Portable iNO for home use.
- gNOped 529: NO wound-healing gas therapy.
- Next Owner: HPV Inhibition Gel.
- Neuro Order: NO Far-Infrared Supramolecular Gel.
- iNOrinse: Nasal Salts.
- CHEVVNO: NO Solid-Toothpaste Tablet.
- VisionPure: Products for Pets.
- Reslinket: Exhaled Breath Detection.
- COlinkeNOglow: Exhaled Breath Detection.